Drugs / GAMCEMETINIB
GAMCEMETINIB
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05445440 | Sep → Nov 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05284890 | May → Jul 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04958291 | Aug → Dec 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04718636 | Sep 2020 → Aug 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04268394 | Mar 2020 → Jun 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03554993 | May 2018 → Jul 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04947579 | Aug 2021 → Feb 2023 | ankylosing spondylitis | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAMCEMETINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314585 ↗ |
| Known as | BMS-986371 | “CC-99677 (BMS-986371) is a novel, small-molecule covalent inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MK2).” PMID 42167889 ↗ May 2026 |
| Known as | CC-99677 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05284890 ↗ |
| Action | Inhibit | “CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases” PMID 35982464 ↗ Aug 2022 |
| Modality | Small molecule | “CC-99677 (BMS-986371) is a novel, small-molecule covalent inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MK2).” PMID 42167889 ↗ May 2026 |
| Route | Oral | “Dosed orally, CC-99677 is efficacious in a rat model of ankylosing spondylitis.” PMID 35691544 ↗ Jun 2022 |